Publications

May 30, 2023 Cell Rep

Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence

Hastie KM, Yu X, Ana-Sosa-Batiz F, Zyla DS, Harkins SS, Hariharan C, Wasserman H, Zandonatti MA, Miller R, Maule E, Kim K, Valentine KM, Shresta S, Saphire EO

Apr 1, 2023 Antiviral Res

SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model

Alves RPDS, Wang YT, Mikulski Z, McArdle S, Shafee N, Valentine KM, Miller R, Verma SK, Batiz FAS, Maule E, Nguyen MN, Timis J, Mann C, Zandonatti M, Alarcon S, Rowe J, Kronenberg M, Weiskopf D, Sette A, Hastie K, Saphire EO, Festin S, Kim K, Shresta S

Sep 12, 2022 Nat Commun

SREBP2-dependent lipid gene transcription enhances the infection of human dendritic cells by Zika virus.

Branche E, Wang YT, Viramontes KM, Valls Cuevas JM, Xie J, Ana-Sosa-Batiz F, Shafee N, Duttke SH, McMillan RE, Clark AE, Nguyen MN, Garretson AF, Crames JJ, Spann NJ, Zhu Z, Rich JN, Spector DH, Benner C, Shresta S, Carlin AF.

May 9, 2022 Pathogens

Acute-phase serum cytokine levels and correlation with clinical outcomes in children and adults with primary and secondary dengue virus infection in Myanmar between 2017 and 2019.

Nwe KM, Ngwe Tun MM, Myat TW, Sheng Ng CF, Htun MM, Lin H, Hom NS, Soe AM, Elong Ngono A, Hamano S, Morita K, Thant KZ, Shresta S, Thu HM, Moi ML.

Apr 12, 2022 Cell Rep

A zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity.

Regla-Nava JA, Wang YT, Fontes-Garfias CR, Liu Y, Syed T, Susantono M, Gonzalez A, Viramontes KM, Verma SK, Kim K, Landeras-Bueno S, Huang CT, Prigozhin DM, Gleeson JG, Terskikh AV, Shi PY, Shresta S.

Nov 1, 2021 Antiviral Res.

SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.

Wang YT, Allen RD 3rd, Kim K, Shafee N, Gonzalez AJ, Nguyen MN, Valentine KM, Cao X, Lu L, Pai CI, Johnson S, Kerwin L, Zhou H, Zhang Y, Shresta S.

Sep 6, 2021 Front Immunol.

The ability of Zika virus intravenous immunoglobulin to protect from or enhance Zika virus disease.

Pinto AK, Hassert M, Han X, Barker D, Carnelley T, Branche E, Steffen TL, Stone ET, Geerling E, Viramontes KM, Nykiforuk C, Toth D, Shresta S, Kodihalli S, Brien JD.

Jun 16, 2021 Viruses.

Emergence of a novel dengue virus 3 (DENV-3) genotype-I coincident with increased DENV-3 cases in Yangon, Myanmar between 2017 and 2019.

Soe AM, Ngwe Tun MM, Nabeshima T, Myat TW, Htun MM, Lin H, Hom NS, Inoue S, Nwe KM, Aye LPP, Fukuta M, Thant KZ, Hasebe F, Morita K, Shresta S, Thu HM, Moi ML.

Jun 1, 2021 Biochem Pharmacol.

Animal models for SARS-Cov2/Covid19 research-A commentary.

Jarnagin K, Alvarez O, Shresta S, Webb DR.

May 5, 2021 Sci Rep.

Repeated exposure to dengue virus elicits robust cross neutralizing antibodies against Zika virus in residents of Northeastern Thailand.

Hattakam S, Elong Ngono A, McCauley M, Shresta S, Yamabhai M.

Jan 29, 2021 PLoS Pathog.

Human FcRn expression and Type I Interferon signaling control Echovirus 11 pathogenesis in mice.

Wells AI, Grimes KA, Kim K, Branche E, Bakkenist CJ, DePas WH, Shresta S, Coyne CB.

Jan 11, 2021 JCI Insight.

Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.

Nair S, Mazzoccoli L, Jash A, Govero J, Bais SS, Hu T, Fontes-Garfias CR, Shan C, Okada H, Shresta S, Rich JN, Shi PY, Diamond MS, Chheda MG.